Forum

Diagnosis is where AI is delivering some of its clearest clinical value, from flagging strokes within minutes of a scan to reading digital pathology slides and supporting precision oncology. According to IG Transformation Partners (IGTPS), the global AI diagnostics market was valued at USD 2.3 billion in 2025 and is projected to reach USD 15.0 billion by 2034, growing at a CAGR of 23.1% during 2026 to 2034. The complete AI diagnostics market report provides the full forecast, segmentation and competitive analysis.

Access the Full Market Report: https://www.igtps.com/report/ai-diagnostics-market

This article covers what the market includes, what is driving it, how it is segmented, where demand is strongest and what the findings mean for vendors, laboratories and health systems.

What Is the AI Diagnostics Market?

The AI diagnostics market covers software, hardware and services that apply machine learning and deep learning to medical images, laboratory samples and clinical data to assist in disease detection, triage and diagnosis across radiology, pathology, cardiology, neurology and oncology.

IGTPS segments the market by component (software, hardware, services), technology (machine learning, deep learning, natural language processing, computer vision, others), application (radiology, pathology, cardiology, neurology, oncology, others), deployment mode (on-premise, cloud-based, hybrid), end user (hospitals, diagnostic laboratories, ambulatory care centers, academic and research institutes, others) and region.

The market is shifting from narrow single-condition algorithms toward multi-condition foundation models and enterprise AI operating platforms that can be deployed and governed across a hospital system from one interface.

AI Diagnostics Market Size, Share and Forecast

IGTPS values the market at USD 2.3 billion in 2025 and USD 2.8 billion in 2026, rising to USD 15.0 billion by 2034, about 6.5 times the 2025 base.

Key Market Trends and Developments

Enterprise AI Operating Platforms

Health systems are moving from single-condition point solutions toward unified platforms that manage dozens of diagnostic algorithms from one governance layer. This reduces integration overhead and lets one vendor relationship cover triage across CT, X-ray and cardiology workflows.

Multi-Condition Foundation Models

Foundation models trained across acute-care indications are replacing narrow algorithms that needed separate clearances and deployments. Aidoc’s CARE foundation model, cleared by the FDA in January 2026 for eleven newly authorized indications alongside three prior clearances, shows how one model can support double-digit use cases in one workflow.

Reduced Alert Fatigue and Central Governance

Radiology departments, emergency rooms and ambulatory imaging centers adopt unified platforms to reduce alert fatigue and standardize escalation of critical findings. Multi-hospital systems are consolidating contracts around platforms that can be centrally monitored and audited.

Regulatory Support

The FDA finalized its Predetermined Change Control Plan guidance for AI-enabled device software functions on 18 August 2025, allowing manufacturers to pre-authorize planned algorithm changes within a single marketing submission. In the United Kingdom, the NHS AI Diagnostic Fund has provided GBP 21 million to 12 imaging networks covering 64 NHS trusts for cancer, stroke and cardiac diagnosis tools.

Review the Report Before You Buy

Request the sample pages to preview the report’s structure, tables and analysis, and confirm it fits your research needs.

Download Free Sample Pages

https://www.igtps.com/download-free-sample/ai-diagnostics-market?P=03

What Is Driving AI Diagnostics Market Growth?

Radiologist and Pathologist Shortages

Persistent shortages across the United States, Europe and parts of Asia force health systems to adopt AI triage that prioritizes the most urgent studies. IGTPS notes that this mismatch between imaging demand and specialist supply is the most cited justification hospital administrators give for approving AI diagnostic budgets.

Faster Detection of Time-Critical Findings

AI triage flags large-vessel occlusion stroke, pulmonary embolism and intracranial hemorrhage within minutes of image acquisition. Hospitals adopting these tools report measurable reductions in door-to-treatment time for stroke and other acute conditions.

Industry Investment

GE HealthCare announced it had topped the FDA’s list of AI-enabled device authorizations for the fourth consecutive year, reaching 100 listed authorizations and targeting more than 200 by 2028, and attributed this to demand for AI that improves diagnostic efficiency and addresses workforce constraints.

Market Restraints and Challenges

IGTPS analysis highlights the following challenges.

• Fragmentation. Specialized AI-native companies and large medical technology firms compete across imaging, pathology and cardiology, and consolidation is ongoing.
• Governance and monitoring obligations. The PCC framework obligates manufacturers and providers to document and monitor iterative algorithm modifications, which adds compliance work.
• Data residency and security. Hospitals often require on-premise deployment to meet patient-data residency and cybersecurity requirements, which complicates cloud scaling.
• Integration with PACS and records. Enterprise platforms must connect with existing radiology and medical record workflows.
• Clinical validation expectations. Competition centers on regulatory clearance breadth and clinical validation.

Market Opportunities and Future Outlook

Companion Diagnostics

Pharmaceutical companies increasingly rely on AI-assisted biomarker analysis to identify patients for precision oncology therapies, creating recurring revenue from clinical trial and companion-diagnostic partnerships. Tempus AI completed its acquisition of Paige for USD 81.25 million to grow its companion-diagnostic dataset. Lunit entered a collaboration with CellCarta in September 2025 to integrate its SCOPE platform into biomarker workflows.

Digital Pathology Foundation Models

Models that predict multiple biomarkers from a single tissue slide cut the cost and turnaround time of companion testing and let vendors expand from single-cancer products to multi-cancer platforms.

CROs and Reference Laboratories

Contract research organizations and reference laboratories integrate third-party AI platforms rather than build proprietary models, expanding the addressable market beyond hospital pathology into drug development.

AI Diagnostics Market Segmentation Analysis

Readers can preview how these segments are presented by requesting the free sample pages.

By Component

Software led because diagnostic algorithms, image analysis engines and decision support platforms are licensed repeatedly across modalities. Vendors such as Aidoc, Viz.ai and Qure.ai monetize through licensing and subscriptions. Services are projected to grow fastest as hospitals move beyond pilots toward enterprise-wide governance, needing implementation, validation and continuous monitoring.

By Technology

Deep learning led because convolutional neural networks underpin most FDA-cleared imaging algorithms for stroke, pulmonary, cardiac and oncology triage. Natural language processing is projected to grow fastest as AI extends into report drafting and structured data extraction. Aidoc’s First Read application received FDA Breakthrough Device Designation in June 2026 for generating preliminary chest X-ray report drafts.

By Application

Radiology led because imaging accounts for the majority of FDA-authorized AI-enabled clearances, with more than 1,400 devices authorized by the end of 2025 and radiology representing roughly three-quarters. Pathology is projected to grow fastest as whole-slide imaging adoption accelerates and models move toward predicting dozens of biomarkers from one slide. Tempus AI’s August 2025 acquisition of Paige added a dataset of nearly seven million digitized slides. Cardiology, neurology and oncology complete the segment.

By Deployment Mode

On-premise led because large hospitals favor locally hosted infrastructure for data residency, cybersecurity and PACS integration, for example Aidoc’s aiOS in hospital data centers. Cloud-based deployment is projected to grow fastest as software-as-a-service lowers upfront costs for smaller hospitals, laboratories and imaging centers. Lunit’s 2025 collaboration with Microsoft on cloud offerings and Qure.ai’s deployment across more than ninety countries illustrate the shift. Hybrid completes the segment.

By End User

Hospitals led because most FDA-cleared diagnostic AI tools are designed for hospital radiology, emergency and cardiology departments. Diagnostic laboratories are projected to grow fastest as digital pathology and companion-diagnostic testing expand into independent and reference laboratory networks. Ambulatory care centers and academic and research institutes complete the segment.

Regional Analysis

North America leads because the United States is the largest market for FDA-cleared AI-enabled devices, with more than 1,400 authorized by the end of 2025. Deep venture investment, including Aidoc’s USD 110 million funding round in July 2025 and Tempus AI’s acquisition of Paige, concentrates capital in the region, and AI triage platforms from Aidoc, Viz.ai and GE HealthCare are integrated into routine stroke, pulmonary and cardiac care.

Asia-Pacific is projected to grow fastest on healthcare digitization, rising imaging volumes and government-backed AI health programs across China, India, Japan and South Korea. India-headquartered Qure.ai has deployed chest X-ray, tuberculosis and stroke-triage tools across more than ninety countries and partnered with Johnson & Johnson MedTech in May 2025, while South Korea’s Lunit has scaled its breast cancer AI ecosystem to more than 330 healthcare providers across the Americas.

Europe, Latin America, and the Middle East and Africa are also covered. IGTPS identifies Germany, Brazil and Saudi Arabia as the largest country markets in their regions, and the United Kingdom as the fastest-growing country market in Europe.

Competitive Landscape and Key Companies

IGTPS describes the market as fragmented, with specialized AI-native companies and large medical technology firms competing across imaging, pathology and cardiology. GE HealthCare, Siemens Healthineers and Philips bundle AI with equipment, while venture-backed specialists such as Aidoc, Viz.ai, Qure.ai and Lunit compete on clearance breadth, clinical validation and enterprise platforms. Other profiled players include Tempus AI, Ibex Medical Analytics, Cleerly, HeartFlow, Median Technologies, Annalise.ai, Butterfly Network and PathAI.

Recent developments cited by IGTPS:

• September 2024: Qure.ai completed a USD 65 million Series D round, including a strategic investment from the Merck Global Health Innovation Fund.
• December 2024: GE HealthCare submitted CleaRecon DL for FDA 510(k) clearance.
• May 2025: Johnson & Johnson MedTech partnered with Qure.ai to expand AI chest X-ray screening for early lung cancer detection.
• July 2025: Lunit partnered with Microsoft to co-develop enterprise-ready cloud offerings.
• December 2025: Lunit announced a collaboration with Daiichi Sankyo on AI-based biomarker and companion-diagnostic research.

Strategic Implications for Industry Participants

AI vendors should build breadth of cleared indications, enterprise platform capability and partnerships with pharmaceutical companies, cloud providers and CROs.

Equipment manufacturers can bundle AI with new systems to defend hospital relationships.

Health systems should consolidate around platforms with central governance, and plan for the monitoring and documentation duties that come with adaptive algorithms.

Laboratories and drug developers can use AI pathology and companion diagnostics to speed biomarker readouts and widen access to precision oncology.

Why Choose IG Transformation Partners

IG Transformation Partners is a market research and industry intelligence provider serving life science, ICT, consumer products and other industries. This report offers 170 to 180 pages and 55 to 65 market tables, delivered as a PDF report with a data sheet and analyst support. IGTPS also offers customized research and consulting services. Its published strengths include strong industry focus, comprehensive reports, value chain analysis, potential market opportunities, quality assurance and regular report updates.

Conclusion

The AI diagnostics market is projected to grow from USD 2.3 billion in 2025 to USD 15.0 billion by 2034 at a 23.1% CAGR. Specialist shortages, faster detection of critical findings and supportive regulation are driving adoption, while companion diagnostics and digital pathology open new revenue pools. Vendors that pair multi-condition platforms with clinical validation, governance services and pharmaceutical partnerships are best placed to lead.

Frequently Asked Questions

What is the AI diagnostics market?

It covers software, hardware and services that apply machine learning and deep learning to medical images, laboratory samples and clinical data to assist in disease detection, triage and diagnosis across radiology, pathology, cardiology, neurology and oncology.

How big is the AI diagnostics market?

IGTPS values the market at USD 2.3 billion in 2025 and USD 2.8 billion in 2026. It is projected to reach USD 15.0 billion by 2034, driven by specialist shortages and expanding regulatory clearances.

What is the CAGR of the AI diagnostics market?

IGTPS projects a CAGR of 23.1% for 2026 to 2034. Growth reflects rising imaging volumes, workforce shortages and growing adoption of AI triage, screening and companion-diagnostic tools.

What is the forecast for AI diagnostics through 2034?

The market is forecast to grow from USD 2.3 billion in 2025 to USD 15.0 billion by 2034. IGTPS expects services, natural language processing, pathology, cloud deployment and diagnostic laboratories to grow fastest.

What are the key trends in AI diagnostics?

Key trends include enterprise AI operating platforms, multi-condition foundation models such as Aidoc’s CARE model cleared in January 2026, reduced alert fatigue through unified governance and regulatory support from the FDA’s PCC guidance.

What is driving AI diagnostics market growth?

The main driver is the growing mismatch between imaging demand and the supply of radiologists and pathologists. AI triage flags time-critical findings such as stroke and pulmonary embolism within minutes, supporting faster treatment.

Which segments lead the AI diagnostics market?

Software, deep learning, radiology, on-premise deployment and hospitals led in 2025. Services, natural language processing, pathology, cloud-based deployment and diagnostic laboratories are projected to grow at the fastest CAGR.

Which region dominates the AI diagnostics market?

North America held the largest share in 2025 at about 44%, supported by the largest base of FDA-cleared AI devices and deep venture investment. Asia-Pacific, with a 24% share, is projected to grow fastest.

Who are the key companies in AI diagnostics?

IGTPS profiles Aidoc, Viz.ai, Tempus AI, Lunit, Qure.ai, Ibex Medical Analytics, Cleerly, HeartFlow, Median Technologies, Annalise.ai, Siemens Healthineers, GE HealthCare, Philips, Butterfly Network and PathAI.

What challenges does the AI diagnostics market face?

Challenges include a fragmented competitive field, documentation and monitoring obligations under the PCC framework, data residency and cybersecurity requirements, integration with PACS and records, and the need for strong clinical validation.

Get the Full AI Diagnostics Market Report

Access forecasts to 2034, segmentation by component, technology, application, deployment mode and end user, regional and country analysis, company profiles and recent developments. Use the findings to guide strategy, investment and partnership decisions.

Related IGTPS Reports

AI in Medical Imaging Market
Relevant for readers following AI image analysis, triage and reporting in radiology.
Explore the Full Report
https://www.igtps.com/report/ai-in-medical-imaging-market

AI Medical Imaging Software Market
Relevant for readers comparing imaging AI software adoption and FDA authorization trends.
Explore the Full Report
https://www.igtps.com/report/ai-medical-imaging-software-market

AI in Healthcare Market
Relevant for readers assessing AI across diagnostics, documentation and drug discovery.
Explore the Full Report
https://www.igtps.com/report/ai-in-healthcare-market

Teledermatology Market
Relevant for readers tracking AI-assisted skin cancer triage and remote diagnosis.
Explore the Full Report
https://www.igtps.com/report/teledermatology-market